# BlossomHill Therapeutics, Inc.: Research, San Diego, United States

> BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics, Inc. Based in San Diego, United States. Founded 2020.

Source: https://millionrounds.com/startup/blossomhill-therapeutics-inc (Millionrounds; every figure on the page links to its filing or article)

United States · [Research startup](https://millionrounds.com/companies)

# BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc.

Email

Funding reported Last round: Series B

Research San Diego, United States

Follow BlossomHill Therapeutics, Inc. and see its new rounds in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Fblossomhill-therapeutics-inc)

Company summary

- **Founded:** 2020 6 years old
- **Team:** 68 51 to 200 people
- **Funding reported:** $257M in dollars
- **Last round:** Series B Dec 2025

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for BlossomHill Therapeutics, Inc. has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc.

is a clinical-stage biopharmaceutical company based in San Diego, California. Founded in 2020, the company focuses on discovering and developing small-molecule drugs aimed at addressing unmet medical needs in oncology and autoimmune disorders. The founders, Dr. J. Jean Cui and Dr. Y. Peter Li, bring extensive expertise in drug design and development, with a history of successful FDA-approved treatments. The company is advancing several clinical-stage drug candidates, including BH-30643, which targets EGFR mutations in non-small cell lung cancer, and BH-30236, aimed at RNA splicing abnormalities in hematologic malignancies. BlossomHill employs innovative approaches such as kinase inhibition and RNA splicing modulation to create precision medicines that enhance therapeutic efficacy while minimizing side effects. With significant funding and a strong focus on overcoming treatment resistance, BlossomHill is positioned to make a meaningful impact in the biopharmaceutical industry.

## What company datasets say BlossomHill Therapeutics, Inc. raised

Funding, as reported

Reported in all **$257M** in dollars

Last round **Series B**

Last round size **$84M**

Last round date **Dec 2025**

Investors listed **5**

## Founders and team

From BlossomHill Therapeutics, Inc.'s own website: 2 on the team.

- **Bihua Chen** Board Member
- **John Schmid** Board Member

## On 4 portfolio pages

Investors who name them

- [OrbiMed](https://millionrounds.com/fund/orbimed)
- [Vivo Capital](https://millionrounds.com/fund/vivo-capital)
- [Brahma Capital](https://millionrounds.com/fund/brahma-capital)
- [Plaisance Capital Management LLC](https://millionrounds.com/fund/plaisance-capital-management-llc)

Each firm lists BlossomHill Therapeutics, Inc. on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

health care biotechnology research therapeutic candidates mutational targeting autoimmune biotech egfr inhibitors drug resistance cancer therapy oncology research small molecule drugs targeted therapy autoimmune autoimmune modulation clk kinase inhibition hospital & health care precision oncology autoimmune treatment

Built with from their website

SAS Analytics Pro Google Tag Manager ACL WordPress.org Kinsta BugHerd Smartsheet CloudFlare Electron Viewport Meta

+8 more

Google Analytics HTTP/3 AIOSEO Duo Security Cloudflare WAF GoDaddy Domains Google Analytics 4 ETQ Reliance QMS

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834
- **Region:** California
- **Revenue:** $1.0M a year, as listed

## Research in United States

Startups like it

- [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai)
- [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences)
- [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit)
- [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos)
- [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences)
- [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic)
- [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines)
- [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences)

## Is this your company?

Add your raise, your deck and your story, and put BlossomHill Therapeutics, Inc. in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)